natural pharmaceuticals derived From Cannabis and other medicinal plants

Company Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug

Tetra Bio-Pharma Inc. Profile

Logo tetrabiopharma rgb web


Tetra Bio-Pharma Added to Leading Cannabis ETF:

Horizons Marijuana Life Sciences Index

  • Only pharmaceutical company to have clinical studies for smoked marijuana
  • Announced Health Canada's Green Light for the Cannabis vs. Fentanyl Trial
  • Announced FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome
  • Signed a letter of intent with a major player of the healthcare specialty industry
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001. 
  • Focused on expanding commercialization partnerships internationally for product pipeline - Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb
  • Signed Agreement with Partner Aphria to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR
  • Concluded its First Sale of Rx Princeps(TM) Inhalation Device
  • Launched a Phase 4 Trial with Cannabis Oils in Partnership with Santé Cannabis



Company Interviews




Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs

  • Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
  • 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products


  • A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
  • Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
  • Pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products


12 Month Stock Chart


Last changed at 08-Aug-2018 02:33PM by AGORACOM